Packaging giant Rexam has reported sales of £4.3bn (€5bn) for the year ended December 2012, up 2% on 2011. Profit before tax was £418m (€482.3m), up 1% on the previous year.
Although the firm’s beverage cans business performed well Rexam’s healthcare packaging unit, which makes bronchial inhalers and injection syringes, had a difficult year largely due to one of its customer’s products coming off patent, according to the company.
Graham Chipchase, Rexam's chief executive, said: "In 2012 we made further encouraging progress. Beverage cans traded well driven by the global growth in specialty cans and a strong recovery in our market share in the US.
“We saw good growth in all our regions with volumes up 6% and organic operating profit increasing by 5%. We are continuing to invest in new lines and capacity to support our future growth.”